Meijome Tomas E, Ekwealor Jenna T B, Hooker R Adam, Cheng Ying-Hua, Ciovacco Wendy A, Balamohan Sanjeev M, Srinivasan Trishya L, Chitteti Brahmananda R, Eleniste Pierre P, Horowitz Mark C, Srour Edward F, Bruzzaniti Angela, Fuchs Robyn K, Kacena Melissa A
Department of Orthopaedic Surgery, Indiana University School of Medicine, Indiana, Indianapolis.
Department of Orthopaedics and Rehabilitation, Yale University School of Medicine, New Haven, Connecticut.
J Cell Biochem. 2016 Apr;117(4):959-69. doi: 10.1002/jcb.25380. Epub 2015 Oct 6.
C-Mpl is the receptor for thrombopoietin (TPO), the main megakaryocyte (MK) growth factor, and c-Mpl is believed to be expressed on cells of the hematopoietic lineage. As MKs have been shown to enhance bone formation, it may be expected that mice in which c-Mpl was globally knocked out (c-Mpl(-/-) mice) would have decreased bone mass because they have fewer MKs. Instead, c-Mpl(-/-) mice have a higher bone mass than WT controls. Using c-Mpl(-/-) mice we investigated the basis for this discrepancy and discovered that c-Mpl is expressed on both osteoblasts (OBs) and osteoclasts (OCs), an unexpected finding that prompted us to examine further how c-Mpl regulates bone. Static and dynamic bone histomorphometry parameters suggest that c-Mpl deficiency results in a net gain in bone volume with increases in OBs and OCs. In vitro, a higher percentage of c-Mpl(-/-) OBs were in active phases of the cell cycle, leading to an increased number of OBs. No difference in OB differentiation was observed in vitro as examined by real-time PCR and functional assays. In co-culture systems, which allow for the interaction between OBs and OC progenitors, c-Mpl(-/-) OBs enhanced osteoclastogenesis. Two of the major signaling pathways by which OBs regulate osteoclastogenesis, MCSF/OPG/RANKL and EphrinB2-EphB2/B4, were unaffected in c-Mpl(-/-) OBs. These data provide new findings for the role of MKs and c-Mpl expression in bone and may provide insight into the homeostatic regulation of bone mass as well as bone loss diseases such as osteoporosis.
C-Mpl是血小板生成素(TPO)的受体,TPO是主要的巨核细胞(MK)生长因子,并且人们认为c-Mpl在造血谱系细胞上表达。由于已表明MK可增强骨形成,因此可以预期,c-Mpl基因被整体敲除的小鼠(c-Mpl(-/-)小鼠)骨量会减少,因为它们的MK较少。然而,c-Mpl(-/-)小鼠的骨量比野生型对照更高。我们利用c-Mpl(-/-)小鼠研究了这种差异的原因,发现c-Mpl在成骨细胞(OB)和破骨细胞(OC)上均有表达,这一意外发现促使我们进一步研究c-Mpl如何调节骨骼。静态和动态骨组织形态计量学参数表明,c-Mpl缺乏导致骨体积净增加,同时OB和OC数量增加。在体外,更高比例的c-Mpl(-/-) OB处于细胞周期的活跃期,导致OB数量增加。通过实时PCR和功能分析检测,体外未观察到OB分化有差异。在允许OB与OC祖细胞相互作用的共培养系统中,c-Mpl(-/-) OB增强了破骨细胞生成。OB调节破骨细胞生成的两条主要信号通路,即MCSF/OPG/RANKL和EphrinB2-EphB2/B4,在c-Mpl(-/-) OB中未受影响。这些数据为MK和c-Mpl表达在骨骼中的作用提供了新的发现,并可能为骨量的稳态调节以及骨质疏松等骨质流失疾病提供见解。